培美曲赛单药治疗老年晚期非小细胞肺癌的疗效和安全性分析  

The clinical efficacy and safety of pemetrexed as monotherapy for elderly patients with advanced non-small cell lung cancer

作　　者：江联萍[1] 李安琪[1] 吴海霞[1] 成少华[1] 谭越[1] 

机构地区：[1]复旦大学附属肿瘤医院闵行分院肿瘤内科,上海200240

出　　处：《实用临床医药杂志》2016年第23期23-25,共3页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金(11525990)

摘　　要：目的观察培美曲赛单药治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法选取40例局部晚期或转移性NSCLC老年患者为研究对象,给予培美曲赛单药二线或三线化疗,评价客观疗效。观察患者生存时间、无疾病进展生存时间和不良反应发生情况。结果 37例患者可评价客观疗效,有效率为18.92%(7/37),疾病控制率83.78%(31/37)。至随访结束,患者中位生存期10.6个月,中位无疾病进展生存时间4.9个月。常见不良反应包括乏力、贫血和肝功能异常,Ⅲ度不良反应包括贫血2例和乏力4例。结论培美曲赛单药治疗晚期NSCLC老年患者,疾病控制率较好,患者耐受性好。Objective To observe the clinical efficacy and safety of pemetrexed as mono- therapy fo elderly patients with advanced non-small cell lung cancer （NSCLC）. Methods A total of 40 patients with advanced local or metastatic NSCLC were included in this study and received peme- trexed monotherapy as second or third line treatment. The response rate of treatment was evaluated, and the survival time, progression-free survival time and adverse reactions were observed. Results Of 40 cases, 37 cases were available for efficacy evaluation. The overall response rate was 18.92% （7/37） and disease control rate was 83.78% （31/37）. The median suvival of all patients was 10.6 months and median progression-free survival time was 4.9 months. The main adverse effects included fatigue, anemia and liver dysfunction. There were 6 cases with 3 grade adverse effects, inclduing 4 cases with fatigue and 2 cases with anemia. Conclusion Findings suggest pemetrexed as monothera- py is potentially well-tolerated and beneficial for elderly patients with advanced NSCLC.

关 键 词：培美曲赛 晚期非小细胞肺癌 老年患者 客观疗效 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]